Corvus Pharmaceuticals, Inc.
CRVS
$3.24
$0.010.31%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -12.11M | -40.22M | -4.26M | -5.70M | -6.65M |
| Total Depreciation and Amortization | 20.00K | 21.00K | 21.00K | 23.00K | 28.00K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 5.09M | 33.74M | -695.00K | 302.00K | 1.85M |
| Change in Net Operating Assets | -1.46M | 138.00K | -545.00K | 219.00K | -391.00K |
| Cash from Operations | -8.47M | -6.32M | -5.48M | -5.16M | -5.17M |
| Capital Expenditure | -- | -- | -- | -- | 0.00 |
| Sale of Property, Plant, and Equipment | 5.00K | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -6.09M | -3.89M | -17.50M | -7.00K | -2.32M |
| Cash from Investing | -6.08M | -3.89M | -17.50M | -7.00K | -2.32M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 18.61M | 50.00K | 16.41M | -- | 0.00 |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 0.00 | 0.00 | 13.97M | -- | -- |
| Cash from Financing | 18.61M | 50.00K | 30.37M | -- | 0.00 |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 4.06M | -10.16M | 7.39M | -5.16M | -7.49M |